B. Stouch

Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens.

R. Washko, A. Rook, G. Nahass, 1999, Journal of the American Academy of Dermatology.

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

P. Kostenuik, M. Stolina, H. Ke, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.

Ian Pyrah, P. Kostenuik, Susan Y. Smith, 2011, Bone.

Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in Rats

Steven W. Martin, P. Kostenuik, S. Morony, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

E. Posvar, D. Padhi, G. Jang, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

Daniel J Lightwood, D. Lacey, Susan Y. Smith, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double‐blind, placebo‐controlled study

A. Kivitz, D. Padhi, G. Jang, 2014, Journal of clinical pharmacology.

Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

D. Salinger, C. Endres, E. Hurh, 2011, Clinical pharmacokinetics.

Application of DBS sampling in combination with LC-MS/MS for pharmacokinetic evaluation of a compound with species-specific blood-to-plasma partitioning.

C. James, B. Stouch, Guifen Xu, 2012, Bioanalysis.

XGEVA(®) (denosumab).

B. Stouch, 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.